Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics